AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance

ALBANY, N.Y., May 9, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing.

"AMRI has an outstanding reputation for quality service, and as we continue to expand our global network, it is critical that we continue to build on that reputation with our customers," said Mr. Marth. "Louis' deep quality experience at a number of pharmaceutical companies – both generic and branded – gives him the understanding of what our customers need. In addition, as AMRI grows toward our goal of achieving $1 billion in annual revenues by 2018, robust accountability for quality is an important business need. Louis is a welcome addition to our team."

Dr. Yu comes to AMRI with over 30 years of leadership experience in the quality and R&D functions of branded and generic pharmaceutical companies. Most recently, he served as executive vice president, global quality & compliance for Perrigo, a manufacturer of private label and branded OTC and generic Rx pharmaceutical products. There, he was responsible for strategic leadership and management of the global quality function. He led traditional quality and regulatory compliance as well as the global patient safety/medical affairs department. Prior to that, he served as vice president of quality for CV Therapeutics, now a division of Gilead. Earlier in his career, he served as the most senior quality leader at Forest Laboratories, Solvay Pharmaceuticals and Par Pharmaceutical as well as with increasing level of responsibilities in the quality and R&D organizations of the J&J Companies.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI

Related Links

http://www.amriglobal.com